Afficher la notice abrégée

Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study

dc.rights.licenseopenen_US
dc.contributor.authorFAUCHIER, L.
dc.contributor.authorBLIN, Patrick
dc.contributor.authorSACHER, F.
dc.contributor.authorDUREAU-POURNIN, C.
dc.contributor.authorBERNARD, M. A.
dc.contributor.authorLASSALLE, R.
dc.contributor.authorDROZ-PERROTEAU, C.
dc.contributor.authorDALLONGEVILLE, J.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOORE, Nicholas
dc.date.accessioned2021-01-25T10:33:06Z
dc.date.available2021-01-25T10:33:06Z
dc.date.issued2020
dc.identifier.issn1532-2092 (Electronic) 1099-5129 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/25977
dc.description.abstractEnAims The real-life benefits and risks of the non-vitamin K antagonist oral anticoagulants for stroke prevention in very elderly patients with atrial fibrillation (AF) are still debated. Methods and results Cohorts of new users of rivaroxaban 15 mg, dabigatran 110 mg, or vitamin K antagonists (VKA) for AF ≥85 years old in 2013 or 2014 were identified in the nationwide French claims database and followed-up for 1 year. Cohorts were compared after 1:1 matching using high-dimensional propensity score. Compared to VKA use and considering 1-year cumulative incidences, risk of stroke, and systemic embolism was not different with rivaroxaban use [hazard ratio 1.14, 95% confidence interval (CI): 0.93–1.40] and lower with dabigatran use (0.77, 95% CI: 0.60–0.99), risk of major bleeding was not different with rivaroxaban use (0.91, 95% CI: 0.74–1.11) and with dabigatran use (0.81, 95% CI: 0.64–1.03), risk of all-cause death was borderline to significance lower with rivaroxaban use (0.91, 95% CI: 0.83–1.00), and lower with dabigatran use (0.87, 95% CI: 0.78–0.97). The risk for a composite of all events above was not different with rivaroxaban use (0.96, 95% CI: 0.88–1.04) and lower with dabigatran use (0.87, 95% CI: 0.79–0.96) as compared with VKA use. The risk for the composite of all events was not different with rivaroxaban use as compared with dabigatran use (1.09, 95% CI: 0.97–1.23). Conclusion This study shows for the first time in more than 25 000 new real-life anticoagulant users for AF aged ≥85 years a neutral overall benefit-risk of rivaroxaban 15 mg vs. VKA and a favourable overall benefit-risk of dabigatran 110 mg vs. VKA on relevant clinical events.
dc.language.isoENen_US
dc.subjectPharmacoEpi-Drugs
dc.title.enReduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
dc.title.alternativeEuropaceen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/europace/euz285en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31638652en_US
bordeaux.journalEP-Europaceen_US
bordeaux.page205-215en_US
bordeaux.volume22en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03120027
hal.version1
hal.date.transferred2021-01-25T10:33:11Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=EP-Europace&rft.date=2020&rft.volume=22&rft.issue=2&rft.spage=205-215&rft.epage=205-215&rft.eissn=1532-2092%20(Electronic)%201099-5129%20(Linking)&rft.issn=1532-2092%20(Electronic)%201099-5129%20(Linking)&rft.au=FAUCHIER,%20L.&BLIN,%20Patrick&SACHER,%20F.&DUREAU-POURNIN,%20C.&BERNARD,%20M.%20A.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée